LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses.

Bullen, Georgia / Galson, Jacob D / Hall, Gareth / Villar, Pedro / Moreels, Lien / Ledsgaard, Line / Mattiuzzo, Giada / Bentley, Emma M / Masters, Edward W / Tang, David / Millett, Sophie / Tongue, Danielle / Brown, Richard / Diamantopoulos, Ioannis / Parthiban, Kothai / Tebbutt, Claire / Leah, Rachael / Chaitanya, Krishna / Ergueta-Carballo, Sandra /
Pazeraitis, Deividas / Surade, Sachin B / Ashiru, Omodele / Crippa, Lucia / Cowan, Richard / Bowler, Matthew W / Campbell, Jamie I / Lee, Wing-Yiu Jason / Carr, Mark D / Matthews, David / Pfeffer, Paul / Hufton, Simon E / Sawmynaden, Kovilen / Osbourn, Jane / McCafferty, John / Karatt-Vellatt, Aneesh

Frontiers in immunology

2021  Volume 12, Page(s) 678570

Abstract: ... BCR) repertoire sequencing to isolate neutralizing antibodies and gain insights into the early ... vaccines highlights the importance of broad cross-reactivity. This study describes deep-mining ... antibody response. This comprehensive discovery approach has yielded a panel of potent neutralizing antibodies ...

Abstract Passive immunization using monoclonal antibodies will play a vital role in the fight against COVID-19. The recent emergence of viral variants with reduced sensitivity to some current antibodies and vaccines highlights the importance of broad cross-reactivity. This study describes deep-mining of the antibody repertoires of hospitalized COVID-19 patients using phage display technology and B cell receptor (BCR) repertoire sequencing to isolate neutralizing antibodies and gain insights into the early antibody response. This comprehensive discovery approach has yielded a panel of potent neutralizing antibodies which bind distinct viral epitopes including epitopes conserved in SARS-CoV-1. Structural determination of a non-ACE2 receptor blocking antibody reveals a previously undescribed binding epitope, which is unlikely to be affected by the mutations in any of the recently reported major viral variants including B.1.1.7 (from the UK), B.1.351 (from South Africa) and B.1.1.28 (from Brazil). Finally, by combining sequences of the RBD binding and neutralizing antibodies with the B cell receptor repertoire sequencing, we also describe a highly convergent early antibody response. Similar IgM-derived sequences occur within this study group and also within patient responses described by multiple independent studies published previously.
MeSH term(s) Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/therapeutic use ; Antibodies, Viral/immunology ; COVID-19/immunology ; COVID-19/prevention & control ; COVID-19/therapy ; Cell Surface Display Techniques/methods ; Data Mining/methods ; Epitopes/immunology ; Humans ; Immunization, Passive/methods ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology
Chemical Substances Antibodies, Monoclonal ; Antibodies, Neutralizing ; Antibodies, Viral ; Epitopes ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
Language English
Publishing date 2021-06-15
Publishing country Switzerland
Document type Journal Article
ZDB-ID 2606827-8
ISSN 1664-3224 ; 1664-3224
ISSN (online) 1664-3224
ISSN 1664-3224
DOI 10.3389/fimmu.2021.678570
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top